Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A loss |
| Therapy | AZD8055 + MK2206 |
| Indication/Tumor Type | breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A loss | breast cancer | sensitive | AZD8055 + MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896). | 27172896 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27172896) | Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. | Full reference... |